EU Court of Justice Advocate General Saugmandsgaard Øe indicates that providing misleading information aimed at undermining the reputation of one drug to the benefit of another drug might constitute a restriction by object (Hoffmann-La Roche)

On 21 September 2017 Advocate General Saugmandsgaard Øe (‘AG’) issued his opinion in F. Hoffmann-La Roche vs Autorità Garante della Concurrenza e del Mercato (AGCM). In his opinion the AG provides guidance to the Court of Justice of the European Union (‘CJEU’) on the various questions raised by the Italian Consiglio di Stato (‘CdS’). The CdS raised these questions in the context of an appeal against a decision of the Italian Competition Authority (‘ICA’), which found that Roche and Novartis concluded an illegal market sharing agreement in the market for eye condition drugs. In general, these questions related to market definition in the pharma sector; the impact of the existence of a licensing agreement on the application of Article 101; and the treatment of the dissemination of misleading

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Simon Troch, Lucille Geraerts, EU Court of Justice Advocate General Saugmandsgaard Øe indicates that providing misleading information aimed at undermining the reputation of one drug to the benefit of another drug might constitute a restriction by object (Hoffmann-La Roche), 21 September 2017, e-Competitions Bulletin December 2017, Art. N° 85409

Visites 98

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues